I Araki1, S Kuno. 1. Department of Urology, Utano National Hospital, Kyoto, Japan. iaraki@utano.hosp.go.jp
Abstract
OBJECTIVES: To find the incidence of voiding dysfunction in Parkinson's disease and to examine the relation between the voiding dysfunction and various indices of the disease (disease severity, disease duration, age, sex, and treatment with antiparkisonian drugs), the presence of voiding dysfunction was quantitatively estimated in patients sampled on the unselected (consecutive) basis. METHODS: Using the international prostate symptom score, lower urinary tract symptoms were quantitatively evaluated in all patients with Parkinson's disease visiting this neurological clinic during 1 month. RESULTS: Of the 203 patients who had completed the questionnaire, 55 (27%) were considered to have symptomatic voiding dysfunction. The degree of lower urinary tract symptoms in these patients was well correlated with the severity of the disease rather than with the disease duration or the age. Thirty three (16%) patients had irritative symptoms alone, whereas three (1.5%) patients had obstructive symptoms alone. The irritative and obstructive symptoms were concomitant in 13 (6%) patients. Quality of life was disturbed by lower urinary tract symptoms, and this disturbance paralleled the severity of the disease. The influence of antiparkisonian drugs on the lower urinary tract symptoms was uncertain. The incidence of lower urinary tract symptoms seemed to be independent of sex, but obstructive symptoms were prevalent in male patients. CONCLUSIONS: This study suggests that voiding dysfunction in patients with Parkinson's disease progressively develops at advanced stages (> or =Hoehn and Yahr stage 3 of the disability). The International prostate symptom score is useful in evaluating the voiding dysfunction of neurodegenerative disease in both men and women, not only reflecting prostatic symptoms.
OBJECTIVES: To find the incidence of voiding dysfunction in Parkinson's disease and to examine the relation between the voiding dysfunction and various indices of the disease (disease severity, disease duration, age, sex, and treatment with antiparkisonian drugs), the presence of voiding dysfunction was quantitatively estimated in patients sampled on the unselected (consecutive) basis. METHODS: Using the international prostate symptom score, lower urinary tract symptoms were quantitatively evaluated in all patients with Parkinson's disease visiting this neurological clinic during 1 month. RESULTS: Of the 203 patients who had completed the questionnaire, 55 (27%) were considered to have symptomatic voiding dysfunction. The degree of lower urinary tract symptoms in these patients was well correlated with the severity of the disease rather than with the disease duration or the age. Thirty three (16%) patients had irritative symptoms alone, whereas three (1.5%) patients had obstructive symptoms alone. The irritative and obstructive symptoms were concomitant in 13 (6%) patients. Quality of life was disturbed by lower urinary tract symptoms, and this disturbance paralleled the severity of the disease. The influence of antiparkisonian drugs on the lower urinary tract symptoms was uncertain. The incidence of lower urinary tract symptoms seemed to be independent of sex, but obstructive symptoms were prevalent in male patients. CONCLUSIONS: This study suggests that voiding dysfunction in patients with Parkinson's disease progressively develops at advanced stages (> or =Hoehn and Yahr stage 3 of the disability). The International prostate symptom score is useful in evaluating the voiding dysfunction of neurodegenerative disease in both men and women, not only reflecting prostatic symptoms.
Authors: P P Sagnier; C J Girman; M Garraway; Y Kumamoto; M M Lieber; F Richard; G MacFarlane; H A Guess; S J Jacobsen; T Tsukamoto; P Boyle Journal: Eur Urol Date: 1996 Impact factor: 20.096
Authors: Y Homma; K Kawabe; T Tsukamoto; H Yamanaka; K Okada; E Okajima; O Yoshida; J Kumazawa; F L Gu; C Lee; T C Hsu; R C dela Cruz; A Tantiwang; P H Lim; M A Sheikh; S D Bapat; V R Marshall; K Tajima; Y Aso Journal: Int J Urol Date: 1997-01 Impact factor: 3.369
Authors: F Stocchi; A Carbone; M Inghilleri; A Monge; S Ruggieri; A Berardelli; M Manfredi Journal: J Neurol Neurosurg Psychiatry Date: 1997-05 Impact factor: 10.154
Authors: T Tsukamoto; Y Kumamoto; N Masumori; H Miyake; T Rhodes; C J Girman; H A Guess; S J Jacobsen; M M Lieber Journal: J Urol Date: 1995-08 Impact factor: 7.450
Authors: A Vallet; N Del Campo; E O Hoogendijk; A Lokossou; O Balédent; Z Czosnyka; L Balardy; P Payoux; P Swider; S Lorthois; E Schmidt Journal: J Neurol Date: 2020-01-29 Impact factor: 4.849